Company intelligence / Profile preview

Glysious

Holte, n/a, Denmark

Ownership: Private
Development stage: Other

Overview

Glysious has demonstrated that its transdermal patch enables controlled, sustained, multi-actives drug release. Feasibility studies with Tetra Pharm Technologies showed a five-fold increase in delivery performance for poorly soluble compounds over conventional matrices, supporting further preclinical research and patent filings. Independent clinical results are not yet published.

Therapeutic areas: DermatologyNeurologyEndocrinology
Modalities: DeviceTransdermal drug delivery systemPatchCreamSprayFoam
Industry: Therapeutic Medical Devices

Partnerships

Tetra Pharm Technologies (joint patent and pipeline development for transdermal drug delivery targeting endocannabinoid system)

Beyond the preview

Go deeper on Glysious.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glysious.

Explore the full profile